Putting the immune system in control

DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after standard of care therapy to delay or prevent disease recurrence. Relapse vaccines are aimed at improving survival by putting the patient’s immune system back in control while tumor burden is low, and the immune system is in relatively good shape.
Read more

A growing pipeline of relapse vaccines

Our lead product DCP-001 is a cell-based vaccine addressing blood cancers with a high risk of relapse. DCP-001 is currently being evaluated in a Phase II clinical trial in acute myeloid leukemia (AML). We are pursuing similar vaccination approaches in other malignancies, including solid tumors.
Read more

Latest News

  • DCprime and University of Bergen Present Data on Novel Animal Model for Cancer Vaccine Research 12 June, 2020 Presentation at EHA Congress reviews development of a humanized immunocompetent mouse model to study DCP-001 as a vaccine for leukemia Leiden, The Netherlands, June 12, 2020 –DCprime, the front-runner in the field of relapse vaccines, in collaboration with the University of Bergen, today announced the presentation of a novel preclinical animal model tailored for cancer vaccine … Read more
  • DCprime Extends International Roll-out of DCP-001 Into the United States 13 May, 2020 Opening of IND follows approval to study DCP-001 in multiple European countries Leiden, The Netherlands, May 13, 2020 –DCprime, the front-runner in the field of relapse vaccines, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for DCP-001, an allogeneic cancer relapse vaccine currently being evaluated … Read more
  • DCprime Receives US FDA Orphan Drug Designation for DCP-001 in Acute Myeloid Leukemia 5 December, 2019 Leiden, The Netherlands, December 05, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to DCP-001 for the treatment of acute myeloid leukemia (AML). DCP-001 is a cell-based vaccine addressing blood cancers with a high risk of relapse … Read more